Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

The Interactions of the 5-HT3 Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium

Author(s): Andrea Cappelli, Stefania Butini, Antonella Brizzi, Sandra Gemma, Salvatore Valenti, Germano Giuliani, Maurizio Anzini, Laura Mennuni, Giuseppe Campiani, Vittorio Brizzi and Salvatore Vomero

Volume 10, Issue 5, 2010

Page: [504 - 526] Pages: 23

DOI: 10.2174/156802610791111560

Price: $65

Abstract

The 5-HT3 receptor (5-HT3R) occupies a special place among the serotonin receptor subtypes because it has been shown to be a ligand-gated ion channel, which is involved in a number of physiological functions and important pathologies. 5-HT3R antagonists have shown an outstanding efficacy in the control of the emesis induced by anticancer chemotherapy and few adverse side-effects, so as to revolutionize the treatment of nausea in cancer patients. This review covers the authors work performed during the past decade in the development of 5-HT3R ligands belonging to the class of arylpiperazine derivatives related to quipazine (quipazine-like arylpiperazines, QLAs) and represents the extension of the review previously published in Current Topics in Medicinal Chemistry in 2002. The discussion is mainly focused on the most significant structure-affinity relationships emerged in the progress of the work and shows how the original ideas have evolved in the recent years.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy